Daniel Cherñavvsky, MD

Research Associate Professor

Dr. Cherñavvsky began his career in basic research at the University of Virginia (UVA) where he had the chance to publish his research as a co-author with a Nobel laurate researcher, Dr. Oliver Smithies. He continued his career as a clinical researcher at the University of Virginia-Center for Diabetes Technology (CDT) where he worked collaboratively with prominent investigators from Europe, South America and USA with the aim to bring Automatic Insulin Delivery (AID) technology to the home. He designed and conducted research projects for 20+ years using technology devices for the treatment and control of diabetes. His studies focused on (i) the effect of using AID in children, adolescents and young adults with T1D (ii) glycemic control using AID during exercise (iii) cognitive and behavioral aspects of children with T1D. He successfully obtained $1,700,000 to create a unique diabetes technology clinic at UVA. Another accomplishment was obtaining the necessary funds and support to run the pivotal clinical trial that led to the regulatory approval of Tandem Control IQ for 6-13 years old children. In 2016 he joined TypeZero as Chief Medical Officer. After the acquisition of TypeZero by Dexcom he worked in industry as Sr. Director Medical affairs at Dexcom. He recently rejoined the CDT at UVA where he continues his breakthrough research and development in diabetes technology with the aim to improve treatments and quality of life for people with diabetes. He has published more than 40 peer review articles and is the senior editor of the first edition of The Artificial Pancreas book. He also serves on the board of the International Society of Pediatric and Adolescent Diabetes.